Antitumor effects of in vivo caveolin gene delivery are associated with the inhibition of the proangiogenic and vasodilatory effects of nitric oxide Agnès Brouet * , 1 , Julie DeWever * , 1 , Philippe Martinive * , Xavier Havaux † , Caroline Bouzin * , Pierre Sonveaux * and Olivier Feron * ,2 University of Louvain Medical School, * Unit of Pharmacology and Therapeutics (UCL-FATH 5349), and † Division of Cardiology, Brussels, Belgium 2 Correspondence: UCL Medical School, Unit of Pharmacology and Therapeutics, FATH 5349, 53 Avenue E. Mounier, Brussels B-1200, Belgium. E-mail: feron@mint.ucl.ac.be <h3>SPECIFIC AIMS</h3> The abundance of caveolin-1 (the structural protein of caveolae microdomains) has been reported to be low or null in many transformed cells and its reexpression to result in substantial inhibition of tumor cell growth. Caveolin has therefore been proposed to function as a tumor suppressor. Still, in tumors, caveolin is expressed unaltered in the vascular compartment and more particularly in endothelial cells where it regulates the activity of the endothelial nitric oxide synthase (eNOS). The main goal of this study was to determine whether an increase in caveolin abundance in endothelial cells lining tumor blood vessels could modulate the vascular effects
/lp/fed-of-american-socs-for-experimental-biology/antitumor-effects-of-in-vivo-caveolin-gene-delivery-are-associated-4EtXiypldm